Co-morbidity of Covid-19 and Stenotrophomonas maltophilia in a Patient with Hodgkin's Lymphoma History from North of Iran

(E-pub Ahead of Print)

Author(s): David Darvishnia, Mahdieh Sadeghi, Ali Sharifpour, Zakaria Zakariaei*, Elham Sadat Banimostafavi, Mahdi Fakhar, Rabeeh Tabaripour

Journal Name: Infectious Disorders - Drug Targets
Formerly Current Drug Targets - Infectious Disorders


Article ID: e160921191124
Become EABM
Become Reviewer
Call for Editor

Abstract:

Immunocompromised patients, especially those hospitalized, are at higher risk for infection with opportunistic pathogens such as Stenotrophomonas maltophilia (S. maltophilia) which is a multidrug-resistant gram-negative bacillus and can cause a challenge in the management of patients with concomitant COVID-19 and S. maltophilia pneumonia. A 71-year-old man with Hodgkin's lymphoma presented with severe respiratory symptoms of COVID-19 and was intubated upon admission and the initial standard treatment for COVID-19 was started for him. The patient subsequently developed superimposed bacterial pneumonia with S. maltophilia. According to that, the patient's intubation tube was removed and a tracheostomy was performed for him. Also, antibiotic treatment was replaced with Colistin and Co-trimoxazole drugs. Finally, after 31 days of hospitalization in the ICU and the aappropriate drug treatment, he was discharged with reduced symptoms and partial recovery. It should be noted that the occurrence of co-infection with multidrug-resistant pathogens such as S. maltophilia requires proper management to select appropriate treatment methods and drugs so that in addition to proper effectiveness, it does not lead to side effects and complications associated with COVID-19 disease.

Rights & PermissionsPrintExport Cite as

Article Details

Article ID: e160921191124
Published on: 03 February, 2021
(E-pub Ahead of Print)
DOI: 10.2174/1871526521666210203220718
Price: $95

Article Metrics

PDF: 138